CSII Key Statistics, Chart & Performance
The current stock price of CSII is 20 USD. In the past month the price increased by 0.81%. In the past year, price increased by 6.95%.
CSII Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CSII. When comparing the yearly performance of all stocks, CSII is one of the better performing stocks in the market, outperforming 94.88% of all stocks.
CSII Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CSII. The financial health of CSII is average, but there are quite some concerns on its profitability.
CSII Financial Highlights
Over the last trailing twelve months CSII reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS decreased by -46.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.08 |
CSII Forecast & Estimates
12 analysts have analysed CSII and the average price target is 17.75 USD. This implies a price decrease of -11.26% is expected in the next year compared to the current price of 20.
For the next year, analysts expect an EPS growth of 28.21% and a revenue growth 8.64% for CSII
CSII Ownership
CSII Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.3 | 192.719B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.76 | 173.049B | ||
| SYK | STRYKER CORP | 23.7 | 137.017B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.78 | 113.066B | ||
| BDX | BECTON DICKINSON AND CO | 14.13 | 59.944B | ||
| IDXX | IDEXX LABORATORIES INC | 43.51 | 51.472B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.47 | 45.675B | ||
| RMD | RESMED INC | 22.12 | 39.65B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.06 | 36.738B | ||
| DXCM | DEXCOM INC | 27.71 | 27.29B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CSII
Company Profile
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. The company is headquartered in St. Paul, Minnesota and currently employs 725 full-time employees. The company went IPO on 2006-06-28. The firm is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The firm has developed orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its peripheral artery disease (PAD) products are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.
Company Info
CARDIOVASCULAR SYSTEMS INC
1225 Old Hwy 8 Nw
ST. PAUL MINNESOTA 55112 US
CEO: Scott R. Ward
Employees: 725
Phone: 16512591600.0
CARDIOVASCULAR SYSTEMS INC / CSII FAQ
What does CSII do?
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. The company is headquartered in St. Paul, Minnesota and currently employs 725 full-time employees. The company went IPO on 2006-06-28. The firm is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The firm has developed orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its peripheral artery disease (PAD) products are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.
Can you provide the latest stock price for CARDIOVASCULAR SYSTEMS INC?
The current stock price of CSII is 20 USD. The price increased by 0.15% in the last trading session.
Does CSII stock pay dividends?
CSII does not pay a dividend.
What is the ChartMill rating of CARDIOVASCULAR SYSTEMS INC stock?
CSII has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for CARDIOVASCULAR SYSTEMS INC?
CARDIOVASCULAR SYSTEMS INC (CSII) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Is CARDIOVASCULAR SYSTEMS INC (CSII) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CSII.
How many employees does CARDIOVASCULAR SYSTEMS INC have?
CARDIOVASCULAR SYSTEMS INC (CSII) currently has 725 employees.